UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

C4 THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK, \$0.0001 PAR VALUE PER SHARE (Title of Class of Securities)

12529R107 (CUSIP Number)

Cobro Ventures Opportunity Fund, L.P.
Attention: Marc Cohen
1000 Wilson Blvd.
#1800
Arlington, VA 22209
(202) 421-7994
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 14, 2021
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d 1(e), 240.13d 1(f) or 240.13d 1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Names of Reporting Persons.				
	I.R.S. Identification Nos. of above persons (entities only)			
			ares Opportunity Fund, L.P.	
2.		the A	ppropriate Box if a Member of a Group (See Instructions)	
	(a) 🗆	(b) ⊠	
3.	SEC Use Only			
4.	4. Source of Funds (See Instructions)			
	wc			
5.		if Die	sclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
5.	CHECK	11 1513	closure of Legal Proceedings is required Fursuant to tiems 2(d) of 2(e)	
6.	Citizer	ıship	or Place of Organization	
	Delaw	are		
		7.	Sole Voting Power	
Nun	nber of		-0-	
Sl	nares	8.	Shared Voting Power	
Bene	eficially	0.	Shared voting rower	
	ned by		None	
	ach	9.	Sole Dispositive Power	
	orting	٥.	Sole Dispositive I ower	
	erson		-0-	
V	Vith	10.	Shared Dispositive Power	
			None	
11.	. Aggregate Amount Beneficially Owned by Each Reporting Person			
	-0-			
12		if the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
12.	Check	II tile	Aggregate Amount in Row (11) Excludes Certain Shares (See instructions)	
13.	3. Percent of Class Represented by Amount in Row (11)			
1.4	0.0% †			
14.	4. Type of Reporting Person (See Instructions)			
	PN			

1. Names of Reporting Persons.					
	I.R.S. Identification Nos. of above persons (entities only)				
	Cobro Opportunity Fund GP, LLC				
2.	2. Check the Appropriate Box if a Member of a Group (See Instructions)				
	(a) 🗆	(b) ⊠		
3.	SEC U	Jse Or	ıly		
4.	4. Source of Funds (See Instructions)				
	AF				
5.		if Die	sclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
0.	Circui	11 1	retoure of regar trocceanings to required turbulant to remo real of recovery		
6. Citizenship or Place of Organization			or Place of Organization		
	Delaw	aro			
	DCIaw	7.	Sole Voting Power		
	nber of		-0-		
	nares eficially	8.	Shared Voting Power		
Ow	ned by		None		
	ach	9.	Sole Dispositive Power		
	orting	٦.	Sole Dispositive I ower		
Person With			-0-		
VVIUI		10.	Shared Dispositive Power		
			None		
11.	A ggro	anto A	amount Beneficially Owned by Each Reporting Person		
11.	Aggre	gate r	miount behenciany Owned by Each Reporting Leison		
	-0-				
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
13.					
15.	2. Freitent of Class Represented by Affiount III Row (11)				
	0.0% †				
14.	Type o	f Rep	orting Person (See Instructions)		
	00				

1.	1. Names of Reporting Persons.				
	I.R.S. Identification Nos. of above persons (entities only)				
_	Marc Cohen				
2.			ppropriate Box if a Member of a Group (See Instructions)		
	(a) □ (b) ⊠				
3.	SEC U	Jse Oı	ıly		
4.	4. Source of Funds (See Instructions)				
	in Source of Funds (See instructions)				
	AF, PF	7			
5.			sclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
5.	Cileck	וו טו	scrosure of Legal Proceedings is Required Pulsuant to frems 2(d) of 2(e)		
6.	Citizei	ıship	or Place of Organization		
	Citizen of the United States of America				
	ı	7.	Sole Voting Power		
Number o			2,127,999*		
Shares		_			
Beneficially		8.	Shared Voting Power		
	ned by				
	Each		-0-		
	orting	9.	Sole Dispositive Power		
	erson				
	<i>N</i> ith		2,127,999*		
l '	/VIUI	10.	Shared Dispositive Power		
		10.	Shared Bispositive Force		
	-0-				
11.	. Aggregate Amount Beneficially Owned by Each Reporting Person				
	2,127,999				
12.	Check	if the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	<u> </u>				
10.	5. Therefore of Glass Represented by fundament flow (11)				
	4.00/ ±				
	4.9% †				
14.	4. Type of Reporting Person (See Instructions)				
	IN				

- * Includes (i) 1,874,805 shares of Common Stock held by M. Cohen, as trustee of the Marc Andrew Cohen Revocable Trust, (ii) 98,936 shares of Common Stock held by M. Cohen, and (iii) stock options exercisable for 154,258 shares of Common Stock within 60 days of June 14, 2021 held by M. Cohen.
- † The percentage of class was calculated based on 43,195,352 shares of the Company's common stock, par value \$0.0001 per share ("**Common Stock**"), outstanding as of May 3, 2021, as set forth in the Company's quarterly report on Form 10-Q, for the period ended March 31, 2021, and filed with the Securities and Exchange Commission (the "**Commission**") on May 13, 2021.

				,
1.	Names of Reporting Persons.			
	I.R.S. Identification Nos. of above persons (entities only) Alain Cohen			
2.	Check	the A	Appropriate Box if a Member of a Group (See Instructions)	
	(a) □ (b) ⊠			
3.	SEC Use Only			
4.	. Source of Funds (See Instructions)			
	AF, PF			
5.	5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6.	Citizer	nship	or Place of Organization	
	Citizen of the United States of America			
		7.	Sole Voting Power	
Number o			1,827,745*	
Shares Beneficially		8.	Shared Voting Power	
Owned by Each			-0-	
Rep	orting	9.	Sole Dispositive Power	
Person With			1,827,745*	
		10.	Shared Dispositive Power	
			-0-	
11.	. Aggregate Amount Beneficially Owned by Each Reporting Person			
	1,827,745			
12.	. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)			
13.	5. Percent of Class Represented by Amount in Row (11)			
	4.2% †	-		
14.			porting Person (See Instructions)	
	IN			

^{*} Includes (i) 1,741,930 shares of Common Stock held by A. Cohen, as trustee of the Alain J. Cohen Revocable Trust, (ii) 62,143 shares of Common Stock held by A. Cohen, and (iii) stock options exercisable for 23,672 shares of Common Stock within 60 days of June 14, 2021 held by A. Cohen.

1.	. Names of Reporting Persons.			
	I.R.S. Identification Nos. of above persons (entities only) Todd Kaloudis			
2.				
3.	SEC Use Only			
4.	Source of Funds (See Instructions)			
_	AF, PF			
5.	5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6.	6. Citizenship or Place of Organization		or Place of Organization	
	Citizen of the United States of America			
	CALLECT	7.		
		, ,	38,090	
Nun	nber of			
Shares Beneficially		8.	Shared Voting Power	
Owned by			-0-	
	lach	9.	Sole Dispositive Power	
	orting erson		38,090	
	Vith			
		10.	Shared Dispositive Power	
			-0-	
11.			Amount Beneficially Owned by Each Reporting Person	-
	38,090)		
12.	Check	if the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
14.		11 (11)	215gregate 1 mount in 100 (11) Dictitues Certain Shares (See instructions)	
13.	B. Percent of Class Represented by Amount in Row (11)			
	0.1% †			
14.	. Type of Reporting Person (See Instructions)			
	IN			

EXPLANATION.

This Amendment No. 1 (this "<u>Amendment</u>") amends and supplements the Schedule 13D (the "<u>Schedule 13D</u>") filed with the Securities and Exchange Commission by the Reporting Persons on October 16, 2020 with respect to the common stock, par value \$0.0001 per share (the "<u>Common Stock</u>"), of C4 Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"). Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

Paragraphs (a), (b) and (c) of this Item 5 are amended and restated as follows:

(a) and (b) As of June 14, 2021, Cobro Ventures directly owned no shares of Common Stock of the Company and Cobro GP beneficially owned no shares of Common Stock of the Company.

As of June 14, 2021, M. Cohen's beneficial ownership consisted of (i) 1,874,805 shares of Common Stock held by M. Cohen, as trustee of the Marc Andrew Cohen Revocable Trust, (ii) 98,936 shares of Common Stock held by M. Cohen, and (iii) stock options exercisable for 154,258 shares of Common Stock within 60 days of June 14, 2021 held by M. Cohen, representing approximately 4.9% of the 43,195,352 shares of Common Stock outstanding as of May 3, 2021, as set forth in the Company's quarterly report on Form 10-Q, for the period ended March 31, 2021, and filed with the Commission on May 13, 2021.

As of June 14, 2021, A. Cohen's beneficial ownership consisted of (i) 1,741,930 shares of Common Stock held by A. Cohen, as trustee of the Alain J. Cohen Revocable Trust, (ii) 62,143 shares of Common Stock held by A. Cohen, and (iii) stock options exercisable for 23,672 shares of Common Stock within 60 days of June 14, 2021 held by A. Cohen, representing approximately 4.2% of the 43,195,352 shares of Common Stock outstanding as of May 3, 2021, as set forth in the Company's quarterly report on Form 10-Q, for the period ended March 31, 2021, and filed with the Commission on May 13, 2021.

As of June 14, 2021, T. Kaloudis' beneficial ownership consisted of 38,090 shares of Common Stock, representing approximately less than 0.1% of the 43,195,352 shares of Common Stock outstanding as of May 3, 2021, as set forth in the Company's quarterly report on Form 10-Q, for the period ended March 31, 2021, and filed with the Commission on May 13, 2021.

(c) On June 14, 2021 Cobro Ventures distributed to its limited partners and sole general partner, Cobro GP, pro rata and without consideration, 2,484,425 shares of the Company's Common Stock. Of these shares, 22,598 shares were distributed to M. Cohen as trustee of Marc Andrew Cohen Revocable Trust, 22,598 shares were distributed to A. Cohen as trustee of Alain J. Cohen Revocable Trust, 4,520 shares were distributed to T. Kaloudis, and 185.633 shares were distributed to Cobro GP.

In turn, Cobro GP, distributed to its members, pro rata and without consideration, the 185,633 shares it received from Cobro Ventures. Of these shares, on the same date Cobro GP distributed, pro rata and without consideration, 92,817 shares to M. Cohen, 61,877 shares to A. Cohen and 30,939 shares to T. Kaloudis.

As a result of the foregoing distributions, each of Cobro Ventures, Cobro GP, M. Cohen, A. Cohen and T. Kaloudis currently beneficially owns less than five percent of the Company's outstanding shares of Common Stock and is no longer required to continue such Schedule 13D filings.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

1 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Dated: June 15, 2021

COBRO VENTURES OPPORTUNITY FUND, L.P.

By: COBRO OPPORTUNITY FUND GP, LLC, its General Partner

By: /s/ Marc Cohen

Marc Cohen, Manager

COBRO OPPORTUNITY FUND GP, LLC

By: /s/ Marc Cohen

Marc Cohen, Manager

MARC COHEN

/s/ Marc Cohen

ALAIN COHEN

/s/ Alain Cohen

TODD KALOUDIS

/s/ Todd Kaloudis

CUSIP No. 12529R107 SC 13D/A Page **9** of 9

EXHIBIT INDEX

Exhibit No. Description

Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended

Joint Filing Agreement

In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of common stock of the Company and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of June 15, 2021.

COBRO VENTURES OPPORTUNITY FUND, L.P.

By: COBRO OPPORTUNITY FUND GP, LLC, its General Partner

By: /s/ Marc Cohen

Marc Cohen, Manager

COBRO OPPORTUNITY FUND GP, LLC

By: /s/ Marc Cohen

Marc Cohen, Manager

MARC COHEN

/s/ Marc Cohen

ALAIN COHEN

/s/ Alain Cohen

TODD KALOUDIS

/s/ Todd Kaloudis